Psychosis Seen In 63% Of Risperdal Alzheimer's Trial Patients, Janssen Says

Janssen identified psychosis in 63% of patients with severe dementia in a Risperdal trial, the company said in a paper submitted to FDA's Psychopharmacologic Drugs Advisory Committee.